Immunome, Inc. (IMNM), a company operating within the biotechnology sector, recently declared that its public offering of 10 million shares of common stock is priced at $20.00 per share. The company anticipates that the offering will close by February 16, 2024.
Immunome also projects that the gross proceeds from the offering, before underwriting discounts, commissions, and various offering expenses are deducted, will amount to $200.0 million.
Furthermore, Immunome has extended a 30-day option to underwriters, permitting them to acquire an additional 1.5 million common shares at the public offering price after accounting for underwriting discounts and commissions.
For this offering, J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities have taken on roles as joint book-running managers. Meanwhile, Wedbush PacGrow takes the lead manager role.
